RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $87 from $82 and keeps an Outperform rating on the shares ahead of the company’s “highly anticipated” launch of aficamten in 2026. The firm is updating its modeling assumptions on opex and revenues to better reflect what early U.S. launch dynamics in 2026 could look like following the December 2025 PDUFA, anchoring to historical competitor data, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $90 from $80 at B. Riley
- Cytokinetics presents additional data from MAPLE-HCM
- Promising Potential of Cytokinetics’ Aficamten Drives Buy Rating Amid Anticipated U.S. Approval
- Private Markets: Anthropic projects $70B in revenue in 2028
- Cytokinetics (CYTK) Faces Class Action Over Misleading Aficamten Claims